retatrutide phase 3 results Results: Trials, Safety, and NHS Outlook – Bolt Pharmacy Retatrutide Phase 3 Results: What

doi: 10.1684/ejd.2019.3691

If you have questions about current weightloss treatments, our clinical team is here to help

The mean duration of exposure to semaglutide or placebo was 34.2 13.7 months

doi: 10.1001/jama.2024.3073 Summary Keywords obesity, obesity pharmacotherapy, precision medicine, personalized treatment, combination therapy, weight management, weight loss Citation Steenackers N, Toumassian J, Deleus E, Mertens A, Lannoo M, Pazmino S, van Laar ADE, Van der Schueren B and Vangoitsenhoven R (2025) Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals